Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus.

Peschken CA, Wang Y, Abrahamowicz M, Pope J, Silverman E, Sayani A, Iczkovitz S, Ross J, Zummer M, Tucker L, Pineau C, Levy D, Hudson M, Hitchon CA, Huber AM, Smith CD, Avina-Zubieta A, Arbillaga H, Ch├ędeville G, Wynant W, Fortin PR; CaNIOS 1000 Faces Investigators.

J Rheumatol. 2019 Feb;46(2):166-175. doi: 10.3899/jrheum.171454. Epub 2018 Sep 15.

PMID:
30219771
2.

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.

Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S.

Rheumatol Int. 2017 Jun;37(6):865-873. doi: 10.1007/s00296-017-3682-9. Epub 2017 Mar 9.

3.

Treatment pathways in an inception lupus cohort over the first three years.

Hanly JG, Sayani A, Doucette S, Iczkovitz S, Terres JAR.

Lupus. 2017 Feb;26(2):119-124. doi: 10.1177/0961203316655213. Epub 2016 Jul 11.

PMID:
27365369
4.

Rosiglitazone use and associated adverse event rates in Canada: an updated analysis.

Iczkovitz S, Dhalla D, Terres JA.

BMC Res Notes. 2015 Sep 29;8:505. doi: 10.1186/s13104-015-1448-6.

Supplemental Content

Loading ...
Support Center